Status:
COMPLETED
FIRAZYR General Drug Use-Results Survey (Japan)
Lead Sponsor:
Shire
Collaborating Sponsors:
Takeda
Conditions:
Hereditary Angioedema (HAE)
Eligibility:
All Genders
Brief Summary
The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Hereditary angioedema (HAE) participants in Japan who receive FIRAZYR for first time in the real world clinical setting.
- Exclusion Criteria
Exclusion
Key Trial Info
Start Date :
November 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 29 2024
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT04057131
Start Date
November 20 2018
End Date
July 29 2024
Last Update
February 21 2025
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Nagoya-city
Nagoya, Aichi-ken, Japan, 453-0046
2
Toyohashi-city
Toyohashi, Aichi-ken, Japan, 441-8570
3
Maebashi-city
Maebashi, Gunma, Japan, 371-8511
4
Asahikawa-city
Asahikawa, Hokkaido, Japan, 070-0034